Value of Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy to Treat Malignant Peritoneal Mesothelioma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2021 Oct 15

PMID 34650746

Citations 2

Authors

Tongfei Wang

Haitao Li

Biaofei Ye

Da Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the clinical efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for treating malignant peritoneal mesothelioma (MPM) and to assess the impact of this approach on patient prognosis.

Methods: A retrospective analysis of 44 patients with MPM was performed. The control group (CNG, N = 23) was treated with CRS combined with postoperative intraperitoneal (IP) chemotherapy, while the observation group (OG, N = 21) was treated with CRS combined with HIPEC. The treatment efficacy, volume of blood loss, operation time, postoperative length of stay, and 3-year survival rate (SR) were compared, and the factors affecting the prognosis of MPM patients were analyzed by multivariate analysis.

Results: The OG showed decreased volume of blood loss and operation time, while also showing increased overall treatment efficacy compared with the CNG. The SR in the OG was 65.22% compared with a rate of 33.33% in the CNG, and the 3-year SR in the OG was significantly higher than that in the CNG. Multivariate analysis revealed that tumor-node-metastasis (TNM) stage, Eastern Cooperative Oncology Group (ECOG) score, and treatment modality were independent risk factors for the prognosis of MPM patients.

Conclusion: CRS combined with HIPEC for MPM has a favorable treatment efficacy and prolongs the survival of MPM patients. Additionally, TNM stage, ECOG score, and treatment modality are independent risk factors for the prognosis of MPM patients.

Citing Articles

Hyperthermic intraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials.

Filis P, Kanellopoulou A, Gogadis A, Filis N, Kamposioras K, Kapoulitsa F Ann Gastroenterol. 2023; 36(1):87-96.

PMID: 36593815 PMC: 9756031. DOI: 10.20524/aog.2023.0758.

Role of Imaging Studies in Evaluating Patients Post Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Fayed M, Angappan S, Oyibo O, Valliani A Cureus. 2022; 13(12):e20601.

PMID: 35103177 PMC: 8782632. DOI: 10.7759/cureus.20601.

References

Le Roy F, Gelli M, Hollebecque A, Honore C, Boige V, Dartigues P . Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. Ann Surg Oncol. 2017; 24(12):3640-3646. DOI: 10.1245/s10434-017-6033-x. View

Wang Y, Jiang Z, Yan J, Ying S . HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma. Dis Markers. 2019; 2019:4183157. PMC: 6390248. DOI: 10.1155/2019/4183157. View

Husain A, Colby T, Ordonez N, Allen T, Attanoos R, Beasley M . Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2017; 142(1):89-108. DOI: 10.5858/arpa.2017-0124-RA. View

Beebe-Dimmer J, Fryzek J, Yee C, Dalvi T, Garabrant D, Schwartz A . Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016; 8:743-750. PMC: 5087771. DOI: 10.2147/CLEP.S105396. View

Jiang Z, Chen T, Chen J, Ying S, Gao Z, He X . Hand-spinning chrysotile exposure and risk of malignant mesothelioma: A case-control study in Southeastern China. Int J Cancer. 2017; 142(3):514-523. DOI: 10.1002/ijc.31077. View

Hassan R, Morrow B, Thomas A, Walsh T, Lee M, Gulsuner S . Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019; 116(18):9008-9013. PMC: 6500142. DOI: 10.1073/pnas.1821510116. View

. Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Eur J Surg Oncol. 2018; 44(11):1800-1804. DOI: 10.1016/j.ejso.2018.06.029. View

Attanoos R, Churg A, Galateau-Salle F, Gibbs A, Roggli V . Malignant Mesothelioma and Its Non-Asbestos Causes. Arch Pathol Lab Med. 2018; 142(6):753-760. DOI: 10.5858/arpa.2017-0365-RA. View

Cui H, Ge H, Bai X, Zhang W, Zhang Y, Wang J . Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med. 2014; 7(5):1083-1088. PMC: 3991504. DOI: 10.3892/etm.2014.1599. View

10.

Cao S, Jin S, Cao J, Shen J, Hu J, Che D . Advances in malignant peritoneal mesothelioma. Int J Colorectal Dis. 2014; 30(1):1-10. DOI: 10.1007/s00384-014-2029-1. View

11.

Elias D, Mariani A, Cloutier A, Blot F, Goere D, Dumont F . Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014; 40(11):1467-73. DOI: 10.1016/j.ejso.2014.06.006. View

12.

Jaster A, Wachsmann J . Serendipitous discovery of peritoneal mesothelioma. Proc (Bayl Univ Med Cent). 2016; 29(2):185-7. PMC: 4790566. DOI: 10.1080/08998280.2016.11929410. View

13.

van Leeuwen B, Graf W, Pahlman L, Mahteme H . Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol. 2007; 15(3):745-53. DOI: 10.1245/s10434-007-9700-5. View

14.

Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard A, Isaac S, Gilly F . Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006; 13(3):405-12. DOI: 10.1245/ASO.2006.05.041. View

15.

Mazurek J, Syamlal G, Wood J, Hendricks S, Weston A . Malignant Mesothelioma Mortality - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017; 66(8):214-218. PMC: 5657894. DOI: 10.15585/mmwr.mm6608a3. View

16.

Nonaka D, Kusamura S, Baratti D, Casali P, Cabras A, Younan R . Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer. 2005; 104(10):2181-8. DOI: 10.1002/cncr.21239. View

17.

Chua T, Chong C, Morris D . Peritoneal mesothelioma: current status and future directions. Surg Oncol Clin N Am. 2012; 21(4):635-43. DOI: 10.1016/j.soc.2012.07.010. View

18.

Shavelle R, Vavra-Musser K, Lee J, Brooks J . Life Expectancy in Pleural and Peritoneal Mesothelioma. Lung Cancer Int. 2017; 2017:2782590. PMC: 5292397. DOI: 10.1155/2017/2782590. View

19.

Lee P, Auyeung K, King D . Pitfalls in diagnosis of early stage malignant peritoneal mesothelioma: a case report. Clin Imaging. 2002; 26(4):263-6. DOI: 10.1016/s0899-7071(02)00424-2. View

20.

Terracini B . Commentary: Past and current asbestos exposure and future mesothelioma risks in Britain. Int J Epidemiol. 2018; 47(6):1756-1757. DOI: 10.1093/ije/dyy175. View